Literature DB >> 28638302

Extended Stability and Sterility of Antihemophilic Factor Human.

Sarah Shields, Abby Kim, Joshua Elder.   

Abstract

OBJECTIVES: Antihemophilic factor human is a factor VIII product used to supplement those with hemophilia. Recent data show treatment benefit and cost saving opportunities if factor products are administered as a continuous infusion rather than conventional bolus dose. This method has not been widely used given the lack of evidence for safe and effective use beyond 3 hours from preparation. The objectives of this study were to determine the physical and chemical stability and sterility of antihemophilic factor human over a 7-day period.
METHODS: Antihemophilic factor human was obtained from the manufacturer. Baseline stability and sterility were determined by factor activity levels along with bacterial and fungal cultures. These tests were also evaluated over a span of 7 days at room temperature and under refrigeration.
RESULTS: Each sample was inspected at the time of delivery and showed no visible signs of physical changes. Factor activity levels were maintained between 88% and 102% of baseline measurements. No growth was observed for bacterial or fungal cultures in any sample after 4 weeks of incubation.
CONCLUSIONS: Antihemophilic factor human maintained physical stability and chemical stability and remained sterile for the 7-day period, allowing extended stability and continuous infusions to be considered.

Entities:  

Keywords:  antihemophilic factor; drug stability; factor VIII, hemophilia

Year:  2017        PMID: 28638302      PMCID: PMC5473393          DOI: 10.5863/1551-6776-22.3.203

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  7 in total

1.  Guidelines for the management of hemophilia.

Authors:  A Srivastava; A K Brewer; E P Mauser-Bunschoten; N S Key; S Kitchen; A Llinas; C A Ludlam; J N Mahlangu; K Mulder; M C Poon; A Street
Journal:  Haemophilia       Date:  2012-07-06       Impact factor: 4.287

2.  Stability of lyophilized and reconstituted plasma/albumin-free recombinant human factor VIII (ADVATE rAHF-PFM).

Authors:  R Parti; A Schoppmann; H Lee; L Yang
Journal:  Haemophilia       Date:  2005-09       Impact factor: 4.287

3.  In vitro stability of lyophilized and reconstituted recombinant activated factor VII formulated for storage at room temperature.

Authors:  Hanne Nedergaard; Susanne Vestergaard; Pernille Theil Jensen; Morten Wagner Kristiansen; Michael Bech Jensen; Per B Ostergaard; Tina Norsell; Jens Bjerre
Journal:  Clin Ther       Date:  2008-07       Impact factor: 3.393

4.  Intermittent injections vs. continuous infusion of factor VIII in haemophilia patients undergoing major surgery.

Authors:  A Batorova; U Martinowitz
Journal:  Br J Haematol       Date:  2000-09       Impact factor: 6.998

5.  Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia.

Authors:  U Martinowitz; J Luboshitz; D Bashari; B Ravid; E Gorina; L Regan; H Stass; A Lubetsky
Journal:  Haemophilia       Date:  2009-02-27       Impact factor: 4.287

6.  In vitro and in vivo stability of diluted recombinant factor VIII for continuous infusion use in haemophilia A.

Authors:  S Revel-Vilk; V S Blanchette; M Schmugge; D S Clark; D Lillicrap; M L Rand
Journal:  Haemophilia       Date:  2009-09-17       Impact factor: 4.287

7.  A study of variations in the reported haemophilia A prevalence around the world.

Authors:  J S Stonebraker; P H B Bolton-Maggs; J Michael Soucie; I Walker; M Brooker
Journal:  Haemophilia       Date:  2009-10-21       Impact factor: 4.287

  7 in total
  1 in total

1.  Stability of Turoctocog Alfa, a Recombinant Factor VIII Product, during Continuous Infusion In Vitro.

Authors:  Masahiro Takeyama; Anne Mette Nøhr; Debra Pollard
Journal:  TH Open       Date:  2020-11-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.